17-18121822-AC-A
Position:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_016239.4(MYO15A):βc.3026delβ(p.Pro1009LeufsTer49) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000342 in 1,460,586 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (β β ). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: not found (cov: 33)
Exomes π: 0.0000034 ( 0 hom. )
Consequence
MYO15A
NM_016239.4 frameshift
NM_016239.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: -1.19
Genes affected
MYO15A (HGNC:7594): (myosin XVA) This gene encodes an unconventional myosin. This protein differs from other myosins in that it has a long N-terminal extension preceding the conserved motor domain. Studies in mice suggest that this protein is necessary for actin organization in the hair cells of the cochlea. Mutations in this gene have been associated with profound, congenital, neurosensory, nonsyndromal deafness. This gene is located within the Smith-Magenis syndrome region on chromosome 17. Read-through transcripts containing an upstream gene and this gene have been identified, but they are not thought to encode a fusion protein. Several alternatively spliced transcript variants have been described, but their full length sequences have not been determined. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 17-18121822-AC-A is Pathogenic according to our data. Variant chr17-18121822-AC-A is described in ClinVar as [Pathogenic]. Clinvar id is 506256.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
MYO15A | NM_016239.4 | c.3026del | p.Pro1009LeufsTer49 | frameshift_variant | 2/66 | ENST00000647165.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
MYO15A | ENST00000647165.2 | c.3026del | p.Pro1009LeufsTer49 | frameshift_variant | 2/66 | NM_016239.4 | P1 | ||
MYO15A | ENST00000583079.1 | n.2659del | non_coding_transcript_exon_variant | 1/1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 genomes
Cov.:
33
GnomAD3 exomes AF: 0.00000403 AC: 1AN: 247954Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 134994
GnomAD3 exomes
AF:
AC:
1
AN:
247954
Hom.:
AF XY:
AC XY:
0
AN XY:
134994
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000342 AC: 5AN: 1460586Hom.: 0 Cov.: 44 AF XY: 0.00000138 AC XY: 1AN XY: 726580
GnomAD4 exome
AF:
AC:
5
AN:
1460586
Hom.:
Cov.:
44
AF XY:
AC XY:
1
AN XY:
726580
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 33
GnomAD4 genome
Cov.:
33
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 25, 2023 | This sequence change creates a premature translational stop signal (p.Pro1009Leufs*49) in the MYO15A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MYO15A are known to be pathogenic (PMID: 17546645). This variant is present in population databases (no rsID available, gnomAD 0.0009%). This variant has not been reported in the literature in individuals affected with MYO15A-related conditions. ClinVar contains an entry for this variant (Variation ID: 506256). For these reasons, this variant has been classified as Pathogenic. - |
Rare genetic deafness Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Dec 21, 2017 | The p.Pro1009fs variant in MYO15A has not been previously reported in individual s with hearing loss, but has been identified in 1/111138 European chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org). Alt hough this variant has been seen in the general population, its frequency is low enough to be consistent with the carrier frequency for recessive nonsyndromic h earing loss. This variant is predicted to cause a frameshift, which alters the protein?s amino acid sequence beginning at position 1009 and leads to a prematur e termination codon 49 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein, and truncating variants in this regio n of the protein in individuals with hearing loss have been previously reported by our laboratory and in ClinVar. In summary, this variant meets criteria to be classified as pathogenic for hearing loss in an autosomal recessive manner based on the predicted impact of the variant. ACMG/AMP Criteria applied: PVS1, PM2, P M1. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at